Last reviewed · How we verify
DMARD
At a glance
| Generic name | DMARD |
|---|---|
| Sponsor | Barts & The London NHS Trust |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug (PHASE3)
- The SetPoint System Safety & Performance Post-Approval Study
- Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis (PHASE3)
- IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD (PHASE1)
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines (PHASE3)
- Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs
- A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
- Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DMARD CI brief — competitive landscape report
- DMARD updates RSS · CI watch RSS
- Barts & The London NHS Trust portfolio CI